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Abstract
Besides its well-known effect on migration and homing of hematopoietic stem/progenitor cells (HSPCs), CXCL12 chemokine also exhibits a cell cycle and survival promoting factor for human CD34 + HSPCs. CXCR4 was suggested to be responsible for CXCL12-induced biological effects until the recent discovery of its second receptor, CXCR7. Until now, the participation of CXCR7 in CXCL12-induced HSPC cycling and survival is unknown. We show here that CXCL12 was capable of binding CXCR7 despite its scarce expression at CD34 + cell surface. Blocking CXCR7 inhibited CXCL12-induced Akt activation as well as the percentage of CD34 + cells in cycle, colony formation and survival, demonstrating its participation in CXCL12-induced functional effects in HSPCs. At steady state, CXCR7 and β -arrestin2 co-localized near the plasma membrane of CD34 + cells. After CXCL12 treatment, β -arrestin2 translocated to the nucleus and this required both CXCR7 and CXCR4. Silencing β arrestin expression decreased CXCL12-induced Akt activation in CD34 + cells. Our results demonstrate for the first time the role of CXCR7, complementary to that played by CXCR4, in the control of HSPC cycling, survival and colony formation induced by CXCL12. We also provide evidence for the involvement of β -arrestins as signaling hubs downstream of both receptors CXCL12 receptors in primary human HSPCs.
Introduction
Hematopoiesis is tightly orchestrated by a precise quiescence/cycling equilibrium that is required for the continuous controlled production of differentiated blood cells. Chemokines and their receptors play an essential role in maintaining the hematopoietic stem/progenitor cells (HSPCs) pool within stem cell niches.
In addition to its well-known effect on HSPC trafficking, the CXCL12/SDF-1 chemokine is a key regulator of hematopoiesis homeostasis, acting at low concentrations as a survival and cell cycle promoting factor for CD34 + HSPCs 1, 2 . We recently demonstrated the pivotal role of two downstream effectors of the PI3K/Akt pathway, FoxO3a and mTOR, as key signaling nodes in CXCL12/TGF-β-induced control of the cycling/quiescence switch 3 .
CXCR4 was the first identified receptor for CXCL12 4 . It was long considered as the only CXCL12 receptor until the discovery of a second receptor, CXCR7, also known as RDC1 5, 6 .
Studies using CXCR7 deficient mice permitted the demonstration of a crucial role for this receptor in endothelial, cardiac and B-cell development. However, no obvious hematopoietic phenotype could be shown in these mice 7 . The absence of hematopoietic phenotype contrasts with the defects observed in CXCL12 and CXCR4 deficient mice 8, 9, 10 , and supports the hypothesis of distinct developmental roles for CXCR7 and CXCR4.
It has been proposed that, like CXCR4, CXCR7 is involved in the migration and survival of various cell types, and could provide tumor cells with a proliferative advantage 5, 6, 11 . In the hematopoietic system, the expression of CXCR7 is controversial. Some studies reported the expression of this receptor at the cell surface of lymphocytes and monocytes 5, 12, 13 , whereas other investigators could not find any detectable plasma membrane expression 14 . In HSPCs,
For personal use only. on January 15, 2018. by guest www.bloodjournal.org From the low or undetectable plasma membrane expression of CXCR7 observed on CD34 + cells isolated from bone marrow, mobilized peripheral blood or umbilical cordon blood 14, 15 contrasts with its abundant intracellular level 16 .
It has been proposed that CXCR7 might be a non-signaling "decoy" receptor, unable to generate intracellular signals via G protein activation 17 . However, ligand binding to CXCR7 can activate downstream signaling pathways through β -arrestins, two scaffolding proteins that coordinate multiple signaling pathways in addition to their roles in promoting receptor desensitization and trafficking 18, 19, 20, 21, 22 . In the hematopoietic system, it was proposed that CXCR7 can hetero-dimerize with CXCR4 in differentiated cells such as T lymphocytes and contribute to CXCL12-mediated chemotaxis through CXCR4-mediated G protein signaling 7, 17 . Whereas CXCR7 has been proposed to be involved in CXCL12-triggered integrin activation in cooperation with CXCR4 16 , its participation in CXCL12-induced HSPC cycling and survival is unknown. In this context, the present study was aimed to study the role of CXCR7 in the CXCL12-induced effects on human HSPC cycling and survival and to identify its downstream signalisation. We made use of CD34 + cells purified from the peripheral blood (PB) of healthy un-mobilized donors that are mainly in G 0 to perform a synchronized study of the CXCL12-induced G 0 -G 1 transition and proliferation.
Our results show that CXCR7 is nearly undetectable at the plasma membrane of CD34 + cells from PB. In contrast, its intracellular expression is high and partially co-localized with that of CXCR4. Despite the scarce expression of CXCR7 at the plasma membrane of CD34 + cells, specific CXCL12 binding can be documented. We demonstrate that CXCR7 participates, together with CXCR4, in the promoting effects of CXCL12 on CD34 + cell cycling, survival and proliferation through Akt activation and that β -arrestins are signaling hubs downstream of the two receptors.
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Materials and Methods

Immunomagnetic Linand CD34 + cell separation
Linand CD34 + cells were purified from un-mobilized PB of healthy donors with their informed consent by the MACS technology (Miltenyi-Biotech) according to local Institutional Review Board (CTSA Clamart-France). Studies were conducted in accordance with Declaration of Helsinki. CD34 + were selected directly after density gradient separation (Inc -) or after (Inc + ) an overnight incubation as previously described 2 . CD34 + cells were verified 95-98% pure by flow cytometry analysis.
Surface and intracellular CXCR4 and CXCR7 labeling
CD34 + cells were labeled with anti-CXCR4-PE, -CXCR7-PE, -CD34-Percp antibodies or their corresponding isotype controls (Table S1 ). Intracellular labeling was performed as previously described 3 .
CXCL12 AF647 binding assay
CD34 + cells were incubated either with CXCL12 (1.6µg/mL corresponding to 200nM), CXCL11 (3.32µg/mL corresponding to 400nM), anti-CXCR4 and/or -CXCR7 blocking antibodies (10µg/mL), CXCR7 inhibitors (1µM) or respective controls and then incubated with fluorescent CXCL12 AF647 (10ng/mL, Almac Sciences-Scotland) for 3 hours at 37°C (Table S1 ).
Quantitative Reverse Transcription-Polymerase Chain Reaction
Reverse transcription (RT) of total RNA from CD34 + cells was performed as previously described 3 . Specific primer sequences are detailed in Table S2 . Data were normalized on Tata box Binding Protein (TBP) housekeeping gene using the 2ΔΔCT method. 
CXCR4 and CXCR7 coimmunoprecipitation
Coimmunoprecipitation experiment was performed as previously described 23 using anti-CXCR7 or anti-CXCR4 antibodies (Table S1 ).
Western blot
An equivalent number of CD34 + cells per condition were lysed as previously described 23 .
Proteins were loaded in a SDS-polyacrylamide gel and transferred to a PVDF membrane.
Primary antibodies included an anti-phospho-Akt, anti-total Akt, anti-actin or anti-β-arrestin2 (Table S1 ). Alexa Fluor-680 anti-rabbit (Invitrogen) or -800 anti-mouse (Thermo-Scientific)
antibodies were added to detect specific proteins using an Odyssey scanner.
β -arrestin Silencing
Freshly purified CD34 + cells were transfected with 2 µM ON-TARGET plus SMART pool siRNA targeting human β -arrestin2 (Thermo-Scientific) or ON-TARGET plus non targeting pool siRNA (Thermo-Scientific) using Amaxa Human CD34 + Cell Nucleofector Kit (Lonza)
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CD34 + cell cultures
Freshly purified CD34 + cells were incubated in a serum-and cytokine-free StemαA medium (Stem-Alpha, France) in the presence or absence of CXCL12 (0.5ng/mL), blocking anti-CXCR4, -CXCR7 or isotype control (10µg/mL). In some experiments, cells were incubated with CXCR7 inhibitory compounds: CCX704 (control), CCX771 and CCX733 (1µM or 100nM).
For colony formation, PB CD34 + cells were plated at a density of 2000 cells/mL in methylcellulose media supplemented with cytokines according to the manufacturer's instructions (Methocult® GF+ H4435, Stem cell technologies).
Intracellular detection of cyclin expression, cell cycle fractions and phospho-Akt level
Cyclin expression and cell cycle analysis were performed using anti-Ki67-FITC or anticyclin A, B1, D1, D3-FITC antibodies (Table S1) as previously described 3 .
For phospho-Akt detection, cells were stimulated 15 min in a serum-and cytokine-free StemαA medium in the presence or absence of CXCL12 (0.5ng/mL) and stained with an antiphospho-Akt antibody.
Statistical analysis
Data were expressed as means +/-SD. The significance between the different conditions and their control was determined by Student's t test for paired samples. A p-value ≤ 0.05 was considered significant.
Results
CXCR7 is mainly expressed in intracellular compartments and is partly co-localized with CXCR4 in PB CD34 + cells
We first verified the specificity of anti-CXCR7 antibodies (9C4 and 11G8 clones) in SkBr3 cells expressing no CXCR7 mRNA (Supplemental Material and Method section and Supplemental Figure 1A ). When CXCR7 negative SkBr3 cells were transfected with a CXCR7-YFP plasmid, we showed that only CXCR7-YFP plasmid transfected cells were stained by both anti-CXCR7 antibodies (Supplemental Figure 1B and C).
We further showed that CXCR7 was expressed at the cell surface of Lincells from unmobilized PB and that a very low percentage of Lincells co-expressed CXCR7 and CD34 (0.126%±0.06%, n=3; Figure 1A ). However, CXCR7 was mostly undetectable at the membrane of freshly purified (Inc -) PB CD34 + cells ( Figure 1B ). Whereas a low percentage of CD34 + cells expressed CXCR4 at the plasma membrane (6.8%±1.6%, n=3, Figure 1B ), more than 85% of PB CD34 + cells expressed both intracellular CXCR7 and CXCR4 (87.8±10.9% and 95.3%±5.8%, respectively; n=3-5, Figure 1C ).
As previously reported 2 , overnight incubation on plastic (Inc + ) increased CXCR4 cell surface expression (6.77%±1.61% vs. 65.27%±6.38%, p≤0.001, n=3, Figure 1B ). In contrast, CXCR7 remained mostly undetectable at the plasma membrane after overnight incubation on plastic ( Figure 1B ). However, the percentage of cells expressing intracellular CXCR4 or CXCR7 was unchanged between Incand Inc + cells (95.3%±5.8% vs. 85%±21.9% and 87.8±10.9% vs.
84.8±7.7% respectively; Figure 1C ). We also demonstrated the presence of CXCR7 mRNA in freshly purified PB CD34 + cells and showed that its relative expression was similar to that of CXCR4 (0.7±0.4 vs. 1.0±0.4 AU, respectively; Figure 1D ).
Because of the presence of intracellular CXCR4 and CXCR7 in CD34 + cells, we investigated whether both receptors were co-localized on PB CD34 + cells. Confocal microscopy analysis
For personal use only. on January 15, 2018. by guest www.bloodjournal.org From showed that a small proportion of CXCR4 and CXCR7 were co-localized in the CD34 + cell cytoplasm and that a one hour incubation with CXCL12 (0.5ng/mL) did not modified their cell distribution ( Figure 1E ). Receptor co-localization prompted us to investigate whether CXCR4/CXCR7 heterodimers exist in HSPCs. Given the small number of CD34 + cells purified from unmobilized PB, co-immunoprecipation experiments were performed in KG1 cells as a model of CD34 + HSPC that expressed a similar scarce plasma membrane CXCR7. Figure 1F shows the presence of CXCR4/CXCR7 heterodimers in KG1 CD34 + cells regardless of whether they were treated or not with CXCL12 (0.5ng/mL).
Altogether, our results show that CXCR7 is expressed in PB CD34 + cells where it is partly co-localized with CXCR4 and that its expression is mainly restricted to the intracellular compartment.
CXCL12 binds to CXCR7 in PB CD34 + cells
CXCR7 was reported to internalize constitutively and to rapidly recycle back to the cell surface 16, 21 . By using Alexafluor-647-coupled CXCL12 (CXCL12 AF647 ), a fully functional and specific CXCL12 chemokine derivative 24, 25 , we showed that CXCL12 AF647 could bind to CD34 + HSPCs (n=4; Figure 2A ). CXCL12 AF647 binding was specifically inhibited by addition of CXCL12 (9.5±2.6 AU vs. 100 AU, p≤0.001, n=4; Figure 2B ). Pre-treatment with either CXCR4 and/or CXCR7 blocking antibodies (9C4 and 11G8 clones) inhibited CXCL12 AF647 binding compared to control IgG (41.6±5.0 AU vs. 100 AU, p≤0.001, n=4; 70.6±9. 5 Figure 2C ). More importantly, CXCL12 AF647 binding was also inhibited by addition of CXCL11, the other natural ligand of CXCR7 (65.8±17.4 AU vs. 100 AU, p≤0.05, n=4; Figure 2B ).
We also performed 125 I-CXCL12 radiobinding assay on KG1 cells as a model of CD34 + cells and showed that addition of either CXCL12, CXCL11, anti-CXCR7 antibody (11G8 clone) or CCX771 inhibitor inhibited 125 I-CXCL12 binding to CXCR7 (Supplemental Figure 2 ).
These data demonstrate that CXCR7 can bind its natural ligands CXCL12 and CXCL11 despite of its low membrane expression in CD34 + cells.
The cell cycling promoting effect of CXCL12 on CD34 + cells is mediated by both CXCR7 and CXCR4
We analyzed the respective contribution of CXCR7 and CXCR4 in the modulation of cyclin and inhibitor of cyclin dependent kinase levels by CXCL12 3 . Figure 3A Figure 5A ). The concurrent inhibition of CXCR4 and CXCR7 did not display any additive inhibition on the CXCL12-promoted survival effect ( Figure 5A) .
Similarly, the CXCR7 antagonists CCX733 (0.85±0.05; p≤0.05, n=3) or CCX771 (0.76±0.10;
p≤0.05, n=3) significantly inhibited the effect of CXCL12 on CD34 + cell survival whereas the CCX704 control compound was ineffective ( Figure 5A ). Addition of CXCR4 and CXCR7 blocking antibodies or inhibiting compounds also reduced the CXCL12 priming effect on colony formation by PB CD34 + cells ( Figure 5B ). This reduction similarly affected multipotent progenitors (CFU-Mix) as well as progenitors of erythroid (BFU-E), granulomacrophagic (CFU-GM) and granulocytic (CFU-G) lineages ( Figure 5B ).
These results indicate that CXCR7, in cooperation with CXCR4, mediates the survival and colony formation promoting effects of CXCL12 on PB CD34 + cells.
CXCR7 and CXCR4 mediate the CXCL12-induced Akt phosphorylation in PB CD34 + cells through β -arrestins
Confocal analysis showed that β -arrestin2 is expressed in the cytoplasm of freshly purified CD34 + cells and was partially co-localized with CXCR7 ( Figure 6A) . A 45-minute incubation with CXCL12 (0.5ng/mL) induced translocation of β -arrestin2 to the nucleus ( Figure 6A ).
This nuclear translocation was inhibited after neutralization of either CXCR4 or CXCR7 with specific antibodies or antagonists (0.63±0.06 and 0.53±0.15 vs 0.88±0.07 respectively, p≤0.05; Figure 6 B ).
CXCL12-promoted signaling pathways include the PI3K/Akt axis 3 . Therefore, we investigated whether CXCR7 could affect Akt phosphorylation in response to CXCL12. As expected, CXCL12 (0.5ng/mL) increased the percentage of phospho-Akt expressing cells, compared to the basal level of phospho-Akt in cells treated with CCX704 or isotypic antibody controls ( Figure 6C ). Blocking either CXCR7 or CXCR4 prevented the CXCL12-induced Akt phosphorylation ( Figure 6C ), whereas simultaneous inhibition of both receptors did not show any additive effect (0.21±0.21, 0.07±0.04 and 0.13±0.14 respectively, n=3-4, Figure 6C ).
We next investigated whether β -arrestin2 participated in CXCL12-induced Akt phosphorylation by silencing β -arrestin2 using siRNA. Such a treatment reduced β -arrestin2
protein expression by 61.7±18.9% in CD34 + cells (p≤0.05, n=3; Figure 6D ). CXCL12 (0.5ng/mL) induced Akt phosphorylation in scramble siRNA treated CD34 + cells, which progressively decreased after 5 min stimulation. In contrast, β -arrestin2 siRNA markedly reduced the maximal level of CXCL12-induced-Akt phosphorylation ( Figure 6D ). A similar inhibition was observed using another siRNA targeting both β -arrestin1 and β -arrestin2 (data not shown).
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Discussion
Hematopoiesis is a tightly regulated process resulting from a balance between HSPC quiescence for "stemness" maintenance, proliferation/differentiation for blood cell supply and mobilization. The CXCL12/SDF-1 chemokine plays a crucial role in this equilibrium within stem cell niches 4, 26, 27 . We have previously shown that CXCL12 induces HSPC survival and cycling at low concentration (0.5ng/mL) 1, 2 and that this process involves the activation of the Akt/mTOR/FoxO3a pathway 3 . CXCL12 was initially thought to activate a single CXCR4 receptor, which participates in normal and malignant cell trafficking. Recently, a second receptor for CXCL12, named CXCR7, was discovered; however, its expression in HSPCs and its role in CXCL12-induced cell migration remained controversial 5, 13, 14, 15, 16, 17, 19 . Furthermore, its involvement in the control of cell cycling and survival induced by CXCL12 had never been studied in human HSPCs.
The present study shows that CXCR7 is expressed in PB CD34 + HSPCs, where this receptor is found in the intracellular compartments, partly co-localized with CXCR4. Despite its scarce plasma membrane expression, CXCR7 binds CXCL12 and participates, together with CXCR4, to promote the survival and cycling effect of CXCL12 on HSPCs, via the β -arrestindependent activation of Akt.
In contrast to CXCR4, the expression profile of CXCR7 has not been extensively studied in CD34 + cells. In these cells, its expression has been reported to be mostly intracellular while its membrane expression is controversial since it was reported either not expressed or expressed at very low levels in CD34 + cells purified from either bone marrow, cord blood or mobilized peripheral blood 14, 15, 16 . In the present study, we show that CXCR7 is expressed in CD34 + cells from un-mobilized PB. However, whereas CXCR7 and CXCR4 mRNA levels are comparable, their subcellular distribution is different since, in contrast to CXCR4, CXCR7 is
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Despite these quantitative limitations, CXCR7 can bind its two natural ligands CXCL12 and CXCL11 at the surface of PB CD34 + cells. The disconnection between the CXCR7 biological effect and the scarce plasma membrane expression detected on these cells is still not understood. Such discrepancy may reflect a post-translation regulation of the protein as proposed in neurons 28 . It may also attest for other mechanisms including GPCR oligomerization and regulation of GPCR export by escort proteins 29 . A constant recycling of a small CXCR7 pool on the outer leaflet of the plasma membrane as reported in human T lymphocytes and umbilical cord blood CD34 + cells 16 can also be suggested.
CXCR7 has been reported to play a role in the CXCL12-induced effects alone or together with CXCR4. Whereas CXCL12 regulated the adhesion, proliferation and angiogenesis of endothelial progenitors through CXCR4 and CXCR7, it participated in their survival effect through CXCR7 alone 30 . In lymphocytes, it is suggested that both receptors are involved in rapid CXCL12-triggered integrin activation 16 and that CXCR4/CXCR7 heterodimers regulated CXCL12-promoted chemotaxis 16, 17, 30 . Although CXCR7 has been shown to participate in the control of cell cycle gene expression in a murine adenoma cell line 31 survival and (iv) colony formation of CD34 + cells in response to CXCL12, demonstrate the participation of CXCR7, together with CXCR4 in these biological effects. Our data are in agreement with recent studies reporting that whereas CXCR7 and CXCR4 can mediate distinct effects of CXCL12, they can also act in concert through heterodimerization 16, 17, 32 for other biological effects 11, 30 . In our study, the detection of CXCR7-CXCR4 heterodimers in a Signaling pathways activated in response to CXCL12 include MAPK and PI3K/Akt axes 16, 32, 33 . It has been reported that CXCR7 participates in CXCL12-induced Akt activation in myelo-monocytic and prostate cancer cells 15, 33 but not in T lymphocytes 16, 33 , suggesting that the participation of CXCR7 in Akt activation could be cell-dependent. We have previously shown that the PI3K/Akt pathway activation participates in CD34 + cell cycling in response to low concentrations of CXCL12 3 . Our present results showing that the Akt phosphorylation is dependent on both receptors, demonstrates that CXCR7, together with CXCR4, activates the Akt signaling pathway in PB CD34 + cells.
Except in astrocytes 34 , CXCR7 does not to activate G protein-dependent signaling pathways in response to CXCL12 17 . However, it can transduce cell signaling through β -arrestins and was proposed to be a "β-arrestin-biased receptor" 19, 22 . β -arrestin is known to operate as a scaffold protein for modulating signal transduction 18, 22 and to participate in cell cycle control
For personal use only. on January 15, 2018. by guest www.bloodjournal.org From and proliferation through direct activation of gene transcription 35 . In the present study, we show that CXCR7 and β -arrestin2 co-localize close to the plasma membrane in freshly purified PB CD34 + cells. Following CXCL12 treatment, most β -arrestin2 translocates into the nucleus. While β -arrestin2 usually displays a cytoplasmic distribution due to constitutive nuclear export 36 , it also undergoes active nuclear import and has been shown to accumulate in the nucleus following stimulation of the odorant GPCR hOR17-4 in spermatozoa 37 . In these cells, the nuclear accumulation of β -arrestin2 may be implicated in the control of gene expression during the early steps of fertilization. It is therefore possible that the translocation In conclusion, the present study reveals for the first time an essential role of CXCR7, together with CXCR4, in the control of CD34 + survival, cell cycling and colony formation induced by
For personal use only. on January 15, 2018. by guest www.bloodjournal.org From CXCL12. It also provides evidence for the involvement of β -arrestins as signaling hubs downstream of CXCL12-activated receptors. Therefore, our results revisit the oversimplified model based on the role of the monogamous CXCR4/CXCL12 couple in HSPC regulation 43 and integrate CXCR7 as an actor of the quiescence/cycling balance of HSPCs participating in hematopoiesis homeostasis and stem cell protection within bone marrow niches.
For personal use only. on January 15, 2018. by guest www.bloodjournal.org From For personal use only. on January 15, 2018. by guest www.bloodjournal.org From (F) KG1 cells (4.10 7 ) were incubated with or without CXCL12 (0.5ng/mL) for 5 minutes, lysed, immunoprecipated with anti-CXCR4 or anti-CXCR7 antibodies and immunoblotted with anti-CXCR7 antibody. The percentage of CXCL12 AF647 binding inhibition was determined using the formula previously described 24 (D) Scramble or β -arrestin2 siRNA transfected CD34 + cells were incubated with CXCL12 (0.5ng/mL) for 5, 10, 15 and 30 minutes. Western blot was then performed and membrane was immunoblotted with specific antibodies against pAkt, total Akt, actin and β -arrestin2.
Figure Legends
Histogram shows the percentage of β -arrestin2 expressing CD34 + cells after scramble or β -arrestin2 siRNA transfection. * indicates significance between conditions (p≤0.05).
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